305 related articles for article (PubMed ID: 15655734)
1. Facial lipohypertrophy in HIV-infected subjects who underwent autologous fat tissue transplantation.
Guaraldi G; De Fazio D; Orlando G; Murri R; Wu A; Guaraldi P; Esposito R
Clin Infect Dis; 2005 Jan; 40(2):e13-5. PubMed ID: 15655734
[TBL] [Abstract][Full Text] [Related]
2. Correction of facial lipoatrophy using autologous fat transplants in HIV-infected adolescents.
Dollfus C; Blanche S; Trocme N; Funck-Brentano I; Bonnet F; Levan P
HIV Med; 2009 May; 10(5):263-8. PubMed ID: 19178590
[TBL] [Abstract][Full Text] [Related]
3. Treatment of facial lipoatrophy via autologous fat transfer.
Cohen G; Treherne A
J Drugs Dermatol; 2009 May; 8(5):486-9. PubMed ID: 19537373
[TBL] [Abstract][Full Text] [Related]
4. Treatment of facial lipoatrophy in HIV-infected patients.
Prescrire Int; 2008 Aug; 17(96):170. PubMed ID: 19492497
[TBL] [Abstract][Full Text] [Related]
5. Persistence of lipoatrophy after a four-year long interruption of antiretroviral therapy for HIV1 infection: case report.
Parruti G; Toro GM
BMC Infect Dis; 2005 Oct; 5():80. PubMed ID: 16202141
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of Coleman lipostructure for treatment of facial lipoatrophy in patients with human immunodeficiency virus and parameters associated with the efficiency of this technique.
Burnouf M; Buffet M; Schwarzinger M; Roman P; Bui P; Prévot M; Deleuze J; Morini JP; Franck N; Gorin I; Dupin N
Arch Dermatol; 2005 Oct; 141(10):1220-4. PubMed ID: 16230558
[TBL] [Abstract][Full Text] [Related]
7. A comparison of lipoatrophy and aging: volume deficits in the face.
Coleman S; Saboeiro A; Sengelmann R
Aesthetic Plast Surg; 2009 Jan; 33(1):14-21. PubMed ID: 18987910
[TBL] [Abstract][Full Text] [Related]
8. Restorative interventions for HIV facial lipoatrophy.
Carey D; Liew S; Emery S
AIDS Rev; 2008; 10(2):116-24. PubMed ID: 18615122
[TBL] [Abstract][Full Text] [Related]
9. Adipose tissue inflammation and liver fat in patients with highly active antiretroviral therapy-associated lipodystrophy.
Sevastianova K; Sutinen J; Kannisto K; Hamsten A; Ristola M; Yki-Järvinen H
Am J Physiol Endocrinol Metab; 2008 Jul; 295(1):E85-91. PubMed ID: 18430964
[TBL] [Abstract][Full Text] [Related]
10. Surgical correction of HIV-associated facial lipoatrophy.
Guaraldi G; Fontdevila J; Christensen LH; Orlando G; Stentarelli C; Carli F; Zona S; de Santis G; Pedone A; De Fazio D; Bonucci P; Martínez E
AIDS; 2011 Jan; 25(1):1-12. PubMed ID: 20975513
[No Abstract] [Full Text] [Related]
11. Contemporary surgical management of HIV-associated facial lipoatrophy.
Funk E; Bressler FJ; Brissett AE
Otolaryngol Head Neck Surg; 2006 Jun; 134(6):1015-22. PubMed ID: 16730549
[TBL] [Abstract][Full Text] [Related]
12. HIV-1 infection alters gene expression in adipose tissue, which contributes to HIV- 1/HAART-associated lipodystrophy.
Giralt M; Domingo P; Guallar JP; Rodriguez de la Concepción ML; Alegre M; Domingo JC; Villarroya F
Antivir Ther; 2006; 11(6):729-40. PubMed ID: 17310817
[TBL] [Abstract][Full Text] [Related]
13. [Treatment of facial lipoatrophy by lipofilling in HIV infected patients: retrospective study on 317 patients on 9 years].
Uzzan C; Boccara D; Lacheré A; Mimoun M; Chaouat M
Ann Chir Plast Esthet; 2012 Jun; 57(3):210-6. PubMed ID: 22218365
[TBL] [Abstract][Full Text] [Related]
14. Therapy insight: Body-shape changes and metabolic complications associated with HIV and highly active antiretroviral therapy.
Falutz J
Nat Clin Pract Endocrinol Metab; 2007 Sep; 3(9):651-61. PubMed ID: 17710086
[TBL] [Abstract][Full Text] [Related]
15. Mitochondrial DNA depletion in adipose tissue of HIV-infected patients with peripheral lipoatrophy.
Buffet M; Schwarzinger M; Amellal B; Gourlain K; Bui P; Prévot M; Deleuze J; Morini JP; Gorin I; Calvez V; Dupin N
J Clin Virol; 2005 May; 33(1):60-4. PubMed ID: 15797366
[TBL] [Abstract][Full Text] [Related]
16. Facial fat volume in HIV-infected patients with lipoatrophy.
Yang Y; Sitoh YY; Oo Tha N; Paton NI
Antivir Ther; 2005; 10(4):575-81. PubMed ID: 16038484
[TBL] [Abstract][Full Text] [Related]
17. A randomized, placebo-controlled trial of rosiglitazone for HIV-related lipoatrophy.
Cavalcanti RB; Raboud J; Shen S; Kain KC; Cheung A; Walmsley S
J Infect Dis; 2007 Jun; 195(12):1754-61. PubMed ID: 17492590
[TBL] [Abstract][Full Text] [Related]
18. Single-slice computed tomography and anthropometric skinfold analysis for evaluation of facial lipoatrophy in HIV-infected patients.
Padilla S; Gallego JA; Masiá M; Gutiérrez F
Clin Infect Dis; 2004 Dec; 39(12):1848-51. PubMed ID: 15578410
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and [corrected] hypoadiponectinemia.
Samaras K; Wand H; Law M; Emery S; Cooper D; Carr A
Diabetes Care; 2007 Jan; 30(1):113-9. PubMed ID: 17192343
[TBL] [Abstract][Full Text] [Related]
20. Early changes in adipokine levels and baseline limb fat may predict HIV lipoatrophy over 2 years following initiation of antiretroviral therapy.
Calmy A; Carey D; Mallon PW; Wand H; Law M; Cooper DA; Carr A; ;
HIV Med; 2008 Feb; 9(2):101-10. PubMed ID: 18257772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
